Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.35 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17023616 | 0.89 | GPR3 (0.43) | GPR3FABP4FABP5ALDH1A1MAPT | |
| SCHEMBL807457 | 0.76 | MAP3K9 (0.45) | GPR3ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15595295 | 0.73 | DRD2 (0.49) | GPR3FABP4FABP5ALDH1A1MAPT | |
| SCHEMBL23878721 | 0.71 | HSD17B10 (0.45) | GPR3ALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL29292345 | 0.71 | ALDH1A1 (0.44) | GPR3ALDH1A1MAPTNPSR1MEN1 | |
| Hydrochloric Acid SCHEMBL5240304 | 0.70 | MAP3K9 (0.49) | GPR3ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL13600308 | 0.70 | GPR3 (0.52) | GPR3ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29767754 | 0.69 | DRD2 (0.49) | GPR3ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL450863 | 0.69 | DRD2 (0.49) | GPR3ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL19752571 | 0.68 | GPR3 (0.40) | GPR3FABP4FABP5ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| WO-2021183980-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AS HERBICIDES | FMC CORPORATION (US) | 2021-09-16 | — | — | WO | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| EP-2888240-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | Alios Biopharma, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031784-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | ALIOS BIOPHARMA, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-4939144-A | PSYCHOLOGICAL DISORDERS; ANXIOLYTIC AND ANTIEMETIC AGENTS | GLAXO GROUP LIMITED (GB) | 1990-07-03 | — | — | US | disclosed |
| US-4937246-A | ABSORBED EASILY FROM INTESTINES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-26 | — | — | US | disclosed |
| EP-0318235-A2 | PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1989-05-31 | — | — | EP | disclosed |
| EP-0317088-A1 | Ketone derivatives | GLAXO GROUP LIMITED (GB) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | SARS1, MAVS, ZC3HAV1 | GPR3 3907/4885FABP4 4132/4885FABP5 2814/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | GPR3 4319/4885FABP4 4157/4885FABP5 2617/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | GPR3 4319/4885FABP4 4157/4885FABP5 2617/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | GPR3 4319/4885FABP4 4157/4885FABP5 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.